As usual, a team of researchers from Fundació ACE, led by Dr. Mercè Boada, has travelled this week to Seville to participate in the 71st edition of the SEN (Spanish Society of Neurology) Annual Meeting. At the conference, held this year on November 19th – 23th, the foundation presented the latest efficacy, safety and biomarker results of the AMBAR (Alzheimer Management by Albumin Replacement) study for the treatment of Alzheimer's.
AMBAR is an innovative study in development, led by the company Grifols, opening a possible new treatment pathway for Alzheimer's disease. The study, in which Fundació ACE participates as a coordinating entity, is based on the hypothesis that most of the beta-amyloid, one of the proteins accumulated in the brains of Alzheimer's patients, is bound to another protein called albumin and circulates in plasma.
Extracting this plasma may flush amyloid-beta peptide from the brain into the plasma, thus limiting the disease's impact on the patient's cognitive functions. So far, a positive effect of the treatment is observed in all the cognitive aspects analysed in this clinical trial, for all patients, both mild and moderate.
In this edition of the SEN Annual Meeting, several professionals of the Foundation have led and participated in different lectures on clinical trials, genetics or ethics and deontology in the field of dementias, among other topics.
This meeting, which is attended by more than 3,000 experts, is the national platform where the latest advances in the neurological field are presented annually.